



Financial Tear Sheet

Corporate Profile

Cambrex Corporation is a custom development and manufacturing organization that specializes in products and services that accelerate the development and commercialization of small molecule therapeutics.

We offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals.

Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage forms.

Primary IR Contact

Stephanie LaFiura
Investor Relations Associate
Phone: 201-804-3037
Fax: 201-804-9852
E-mail:
stephanie.lafiura@cambrex.com

Stock Performance

Symbol CBM (Common Stock)

Exchange NYSE (US Dollar)

Price \$56.30

Change (%) ▲ 0.30 (0.54%)

Volume 304,025

Data as of January 19, 2018 4:02 p.m. ET

Management

Steven M. Klosk
President and Chief Executive Officer

Shawn P. Cavanagh
Executive Vice President and Chief Operating Officer

Samantha M. Hanley
Vice President, General Counsel and Secretary

Gregory P. Sargen
Executive Vice President, Corporate Development and Strategy

Tom Vadaketh
Executive Vice President and Chief Financial Officer

Recent Headlines & Events

There are currently no events scheduled.

Date	Title
January 16, 2018	Cambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at Karlskoga, Sweden Facility
December 05, 2017	Cambrex Recognized for Support of Sustainability Program in Local High Schools
November 09, 2017	CAMBREX WINS API DEVELOPMENT AWARD AT CPhI WORLDWIDE FOR SECOND CONSECUTIVE YEAR

SEC Filings

Filing Date	Form
November 07, 2017	10-Q
November 07, 2017	8-K
November 03, 2017	8-K
November 03, 2017	8-K

Data provided by Nasdaq. Minimum 15 minutes delayed.